In 2026, the iShares S&P 500 ex S&P 100 ETF (XOEF) has outperformed the traditionally stronger iShares S&P 100 ETF (OEF) by 7.85 percentage points, mainly driven by changes in price-to-earnings (P/E) ratios. Despite OEF's current P/E premium of 7.63%, its higher profit margins justify this valuation, and with similar expected earnings growth of 13-15%, OEF is likely to regain its lead. The analysis highlights the importance of valuation changes over growth in ETF performance this year, suggesting OEF's concentration in high-margin companies supports its premium valuation and potential future outperformance.
The comparison between OEF and XOEF ETFs is the subject, with Pluang market data providing context. As of Nov 11, 2026 15:41 WIB, 93 of 150 priced US stocks on Pluang rose while 53 fell. Notable movers include Intel Corp (INTC) at USD 60.75 with a 4.51% gain, United Microelectronics Corp (UMC) at USD 15.70 up 4.39%, and Taiwan Semiconductor Mfg. Co. Ltd. (TSM) at USD 413.80 rising 4.37%.
Rakuten Kobo's 2026 annual report highlights a shift in global reading habits towards niche communities and diverse genres like sports romances, dark romance, and cozy mysteries. The report notes the fragmentation of traditional bestseller lists as r...
Anthropic, an AI company, is reserving up to 20% of its initial public offering (IPO) shares specifically for retail investors. This allocation is significantly higher than the typical 5% to 10% usually offered to individual investors in IPOs. By doi...
DataParser by 17a-4 LLC now supports capturing Zoom AI meeting summaries along with transcripts and recordings for regulatory compliance. This solution helps firms retain, supervise, and search AI-generated content, closing gaps in archiving platform...
At the 9th China International Import Expo (CIIE), Shanghai Zhenhua Heavy Industries (ZPMC) signed import procurement contracts worth RMB 2.835 billion with 12 overseas suppliers including Siemens and ABB. This brings ZPMC's cumulative procurement co...
Devia, an AI platform spun out from Visium, has launched to help biopharma companies, CDMOs, and CROs manage GxP quality deviations more efficiently. It automates the entire deviation lifecycle from reporting to root cause analysis and CAPA, reducing...
